870822-84-7

Usage

Uses

Used in Pharmaceutical Industry:
2-Bromo-6-chloronaphthalene is used as a key intermediate in the synthesis of azolylmethylpiperidines, which are a class of compounds with significant potential as serotonin, dopamine, and norepinephrine reuptake inhibitors. These reuptake inhibitors play a crucial role in the treatment of various neurological and psychiatric disorders, such as depression, anxiety, and attention deficit hyperactivity disorder (ADHD), by modulating the levels of neurotransmitters in the brain.
In the preparation of these azolylmethylpiperidines, 2-Bromo-6-chloronaphthalene serves as a valuable building block, providing a convenient and efficient route to the desired bioactive molecules. Its unique structural features, including the presence of both bromine and chlorine atoms, contribute to its reactivity and compatibility with various synthetic strategies, making it an attractive choice for the development of novel therapeutic agents.

Upstream product

• 7647-01-0 hydrogenchloride 
• 90-11-9 1-Bromonaphthalene 
• 87700-60-5 6-bromonaphthalene-2-carbonyl chloride 
• 5773-80-8 6-bromo-2-naphthoic acid 
• 7499-66-3 6-Bromonaphthalen-2-amine 
• 23417-61-0 6-chloronaphthalen-2-amine 

Relevant academic research and scientific papers

INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN

Compounds and compositions for modulating fibroblast activation protein (FAP) are described. The compounds and compositions may find use as therapeutic agents for the treatment of diseases, including hyperproliferative diseases.

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS

Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and compounds I for use to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).

Pyrazole derivatives, compositions containing such compounds and methods of use

Pyrazoles having a naphthyl group attached are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

Pyrazole derivatives, compositions containing such compounds and methods of use

Pyrazoles having a naphthyl group attached are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.